On Wednesday, the U.S. Food and Drug Administration approved a new pain management drug which could change the way healthcare ...

With GLP-1-related drugs having won the race to weight loss approval, attention at many obesity-focused biopharmas has turned ...

It started as a respiratory illness—or so everyone thought. But it quickly became apparent that SARS-CoV-2, the virus that ...

PMGC Holdings Inc. (NASDAQ: ELAB) shares are trading higher Friday after the company announced that its subsidiary, ...

Bodybuilding has come a long way from the era of simply lifting heavier weights. Today’s athletes are harnessing groundbreaking compounds like Stenabolic and Trenbolone Enanthate to gain muscle, drop ...

People with acid reflux often rely on acid-reducing medications to ease symptoms. Depending on the severity of your symptoms, over-the-counter (OTC) and prescription options are available.

In part 2 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the challenge inherent ...

The FDA has approved Journavx, an oral medication for treating pain that doesn't target the brain like addictive opioids.

The FDA recently approved Vertex Pharmaceuticals Incorporated’s Journavx (suzetrigine), a first-in-class non-opioid medication for treating moderate to severe acute pain in adults. Journavx, approved ...

Unlock the potential of GLP-1 therapies! Join experts to explore cutting-edge strategies for managing cardiovascular & ...

Versant Ventures continues to invest in the increasingly competitive obesity space, this time launching Helicore with $65 ...

Holdings announced that its subsidiary, Northstrive Biosciences has executed a research agreement with a preclinical contract ...